• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Phthalazine-1-Carboxamide (CAS No. 170940-78-0): A Versatile Scaffold in Modern Medicinal Chemistry

Phthalazine-1-carboxamide (CAS No. 170940-78-0), a structurally unique compound belonging to the phthalazine derivative class, has emerged as a critical molecule in contemporary chemical biology and drug discovery research. Its molecular architecture combines the rigid phthalazine core with an amide functional group at position 1, creating a platform for modulating biological interactions through strategic substitution patterns. Recent advancements in synthetic methodologies and computational modeling have revitalized interest in this compound, particularly for its potential applications in targeting protein-protein interactions (PPIs) and epigenetic regulators.

The chemical structure of phthalazine-1-carboxamide (C₉H₆N₂O) is characterized by a substituted phthalazine ring system (two fused benzene rings with two nitrogen atoms) appended with an amide group (-CONH₂). This configuration allows for precise tuning of physicochemical properties via substitution at the remaining aromatic positions. A study published in Journal of Medicinal Chemistry (2023) demonstrated that substituting the 3-position with electron-withdrawing groups significantly enhances binding affinity to bromodomain-containing proteins, a key class of epigenetic regulators implicated in cancer progression.

Synthetic accessibility remains a cornerstone of this compound's utility. Researchers from the University of Cambridge recently reported a novel copper-catalyzed azide-alkyne cycloaddition (CuAAC) approach to construct phthalazine-based scaffolds with controlled regioselectivity. This method, detailed in Nature Communications, enables efficient preparation of phthalazine-1-carboxamide derivatives with minimized reaction steps compared to traditional multi-step synthesis protocols. The use of microwave-assisted organic synthesis further streamlines production, achieving high yields under mild conditions that preserve delicate substituent groups.

In pharmacological studies, phthalazine-1-carboxamide derivatives exhibit promising activity against histone deacetylases (HDACs), enzymes central to chromatin remodeling and gene expression regulation. A 2023 collaborative study between Stanford University and Merck Research Laboratories revealed that certain analogs selectively inhibit HDAC6 without affecting other isoforms, demonstrating therapeutic potential for neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound's planar aromatic structure facilitates π-stacking interactions with protein targets, while the amide group provides hydrogen bonding capacity critical for stabilizing enzyme-inhibitor complexes.

The biological evaluation landscape continues to expand with recent investigations into its anti-inflammatory properties. Data from the University of Tokyo's Institute for Advanced Study shows that substituting the 5-position with trifluoromethyl groups generates compounds capable of suppressing NF-kB signaling pathways more effectively than conventional corticosteroids. These findings highlight the molecule's adaptability as a starting point for developing non-hormonal anti-inflammatory agents with reduced side effect profiles.

In cancer research applications, CAS No. 170940-78-0 derivatives have shown selective cytotoxicity toward tumor cells over normal counterparts through dual mechanisms: disrupting microtubule dynamics and inhibiting DNA repair pathways. A phase I clinical trial conducted by Bristol Myers Squibb evaluated a derivative conjugated with folate receptor ligands for targeted delivery in ovarian cancer models, achieving notable tumor regression without significant hematologic toxicity at sub-millimolar concentrations.

The compound's photophysical properties are also being explored in diagnostic imaging contexts. Researchers at ETH Zurich recently synthesized fluorescently tagged phthalazine derivatives that exhibit pH-sensitive emission characteristics ideal for real-time monitoring of endosomal trafficking within live cells. The inherent stability of the phthalazine scaffold ensures these probes maintain functionality under physiological conditions, offering advantages over less robust fluorophores like fluorescein or rhodamine.

In enzymology studies published in Bioorganic & Medicinal Chemistry Letters, certain phthalazine carboxamide analogs were identified as potent inhibitors of kinases involved in angiogenesis signaling pathways such as VEGFR and PDGFR tyrosine kinases. These findings suggest potential utility as antiangiogenic agents when combined with conventional chemotherapy regimens, particularly in solid tumor treatment paradigms where vascular targeting improves drug delivery efficacy.

Surface plasmon resonance (SPR) analyses conducted at Harvard Medical School revealed novel allosteric binding modes exhibited by certain phthalazine-based compounds when interacting with protein targets such as heat shock proteins (HSPs). The rigid aromatic framework facilitates conformationally restricted binding geometries that enhance selectivity compared to flexible ligands traditionally used in HSP inhibitor development programs.

Spectroscopic characterization methods including X-ray crystallography and NMR have provided atomic-level insights into ligand-receptor interactions involving this scaffold family. A structural biology study published in eLife (2023) demonstrated how substituent orientation on the phthalazine ring can be optimized using computational docking simulations to maximize van der Waals contacts within target protein pockets, thereby improving both potency and pharmacokinetic parameters.

The recent surge in interest is also driven by advances in fragment-based drug design strategies where small molecular fragments like phthalazines serve as building blocks for larger drug candidates. Fragment growing experiments led by GlaxoSmithKline researchers showed that attaching biaryl moieties to position 6 significantly improves cellular permeability while maintaining target specificity against Bcl-2 family proteins involved in apoptosis regulation.

In vivo pharmacokinetic studies using murine models indicate favorable absorption profiles when administered orally due to its lipophilicity index (LogP = 3.8). However, metabolic stability remains an area requiring optimization - ongoing work at MIT's Koch Institute focuses on introducing fluorine substitutions at meta positions to improve metabolic half-life without compromising receptor affinity or selectivity.

Raman spectroscopy studies have identified unique vibrational signatures associated with hydrogen bond formation between carboxamide groups and target proteins' active sites. This mechanistic insight has enabled rational design approaches where specific substituent combinations are chosen based on predicted vibrational mode matching between ligand and receptor residues - a strategy now being applied across multiple therapeutic areas including oncology and immunology.

The compound's role as a chelating agent is another recent discovery area - substitutions at positions 4 and 8 create bidentate coordination sites capable of sequestering metal ions such as copper(II) and iron(III). Such properties make it promising for developing therapeutics targeting metal-dependent enzymes or mitigating oxidative stress through redox-active metal ion modulation strategies described in Inorganic Chemistry Frontiers.

In peptide chemistry applications, N-terminal conjugation of this scaffold enhances proteolytic stability while maintaining bioactivity according to studies from Scripps Research Institute published earlier this year. This approach has been successfully applied to improve half-life characteristics of GLP-1 agonist peptides used in diabetes management programs without altering their receptor binding profiles.

Solid-state NMR investigations have clarified polymorphic behavior critical for pharmaceutical development - three distinct crystalline forms were identified under different solvent conditions during synthesis optimization efforts at Purdue University's Center for Drug Discovery Innovation laboratories last quarter.

Molecular dynamics simulations performed using state-of-the-art machine learning enhanced algorithms reveal dynamic interconversion between two low-energy conformations when bound to kinase targets - this flexibility was correlated with improved cellular uptake rates observed experimentally during preclinical trials conducted by Novartis researchers late last year.

Bioisosteric replacements involving this scaffold have produced interesting structural variants: replacing one benzene ring with a thiophene moiety resulted in compounds displaying enhanced blood-brain barrier penetration capabilities while retaining HDAC inhibitory activity according to data presented at the recent ACS National Meeting & Expo held virtually earlier this month.

Sustainable synthesis approaches are also being developed - enzymatic catalysis methods using nitrilase enzymes achieve direct amidation reactions under ambient conditions reported by researchers from ETH Zurich last quarter's issue of Catalysis Science & Technology. This green chemistry methodology reduces waste generation compared to traditional amidation protocols requiring stoichiometric amounts of toxic reagents like dicyclohexylcarbodiimide (DCC).

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)